






Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

INN	Cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide
ATC codes	J05AR18
Medicine type	Chemical agent
EML status history	Application rejected in 2017 (TRS 1006) for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipedia	Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide 
DrugBank	Cobicistat  , Elvitegravir  , Emtricitabine  , Tenofovir alafenamide 

Recommendations

Section Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

